The Evolution of Mechanical Thrombectomy for Acute Stroke

被引:8
作者
Akbik F. [1 ]
Hirsch J.A. [2 ]
Cougo-Pinto P.T. [3 ]
Chandra R.V. [4 ]
Simonsen C.Z. [5 ]
Leslie-Mazwi T. [2 ]
机构
[1] Department of Neurology, Massachusetts General Hospital, Boston, MA
[2] Neuroendovascular Service, Massachusetts General Hospital, Boston, 02114, MA
[3] Department of Neurosciences and Behavior Sciences, Ribeirão Preto Medical School, Ribeirão Preto, SP
[4] Interventional Neuroradiology, Monash Health, Monash University, Melbourne
[5] Department of Neurology, Aarhus University Hospital, Aarhus
关键词
Acute stroke; Endovascular therapy; Intra-arterial therapy; Ischemic stroke; Large vessel occlusion; Proximal occlusion;
D O I
10.1007/s11936-016-0457-7
中图分类号
学科分类号
摘要
The natural history of an acute ischemic stroke from a large vessel occlusion (LVO) is poor and has long challenged stroke therapy. Recently, endovascular therapy has demonstrated superiority to medical management in appropriately selected patients. This advance has revolutionized acute care for LVO and mandates a reevaluation of the entire chain of stroke care delivery, including patient selection, intervention, and post-procedural care. Since endovascular therapy is a therapy specifically targeting LVO, its application should be restricted to those patients only. Clinical and radiologic parameters need to be considered in patient selection. Data supports that all patients over the age of 18 years presenting with a National Institutes of Health Stroke Scale (NIHSS) of 6 or greater within 6 hours of symptom onset should be considered for emergent endovascular therapy. Radiologically, those with a LVO of the internal carotid artery (ICA) or middle cerebral artery (MCA) M1 portion, intermediate or good collaterals and without large established infarct should be considered endovascular candidates. Selection beyond these parameters remains an open question and is being actively evaluated. In all cases, revascularization should be attempted with a new generation device (stentriever or direct aspiration), as these techniques are most likely to deliver adequate reperfusion. Post-revascularization, patients are closely monitored in an intensive care setting followed by discharge to rehabilitation, if required, or directly home. Patients should be evaluated in delayed fashion to assess recovery (typically at 3 months post-treatment). Ultimately, the poor natural history of ischemic stroke from LVO and the potential significant benefit from endovascular therapy over medical management alone necessitate a national response to ensure we identify and treat all eligible patients as rapidly and effectively as possible. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:1 / 17
页数:16
相关论文
共 95 条
  • [1] Lima F.O., Furie K.L., Silva G.S., Et al., Prognosis of untreated strokes due to anterior circulation proximal intracranial arterial occlusions detected by use of computed tomography angiography, JAMA Neurol, 71, pp. 151-157, (2014)
  • [2] Berkhemer O.A., Fransen P.S.S., Beumer D., Et al., A randomized trial of intraarterial treatment for acute ischemic stroke, N Engl J Med, 372, pp. 11-20, (2015)
  • [3] Campbell B.C., Mitchell P.J., Kleinig T.J., Et al., Endovascular therapy for ischemic stroke with perfusion-imaging selection, N Engl J Med, 372, pp. 1009-1018, (2015)
  • [4] Goyal M., Demchuk A.M., Menon B.K., Et al., Randomized assessment of rapid endovascular treatment of ischemic stroke, N Engl J Med, 372, pp. 1019-1030, (2015)
  • [5] Jovin T.G., Chamorro A., Cobo E., Et al., Thrombectomy within 8 hours after symptom onset in ischemic stroke, N Engl J Med, 372, pp. 2296-2306, (2015)
  • [6] Saver J.L., Goyal M., Bonafe A., Et al., Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke, N Engl J Med, 372, pp. 2285-2295, (2015)
  • [7] Astrup J., Siesjo B.K., Symon L., Thresholds in cerebral ischemia—the ischemic penumbra, Stroke, 12, pp. 723-725, (1981)
  • [8] Jones T.H., Morawetz R.B., Crowell R.M., Et al., Thresholds of focal cerebral ischemia in awake monkeys, J Neurosurg, 54, pp. 773-782, (1981)
  • [9] del Zoppo G.J., Higashida R.T., Furlan A.J., Pessin M.S., Rowley H.A., Gent M., PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. prolyse in acute cerebral thromboembolism, Stroke, 29, pp. 4-11, (1998)
  • [10] Furlan A., Higashida R., Wechsler L., Et al., Intra-arterial prourokinase for acute ischemic stroke. the PROACT II study: a randomized controlled trial. prolyse in acute cerebral thromboembolism, JAMA, 282, pp. 2003-2011, (1999)